Скачать или смотреть The rapidly eolving landscape for high-risk non-muscle invasive bladder cancer treatment

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, comments on the rapidly evolving landscape of high-risk, non-muscle invasive bladder cancer treatment, highlighting the need for new and safer therapies, particularly in the context of BCG shortages and the increasing use of systemic checkpoint inhibitors. Prof. Hayne notes that BCG plus mitomycin is a widely available and effective first-line treatment, but acknowledges the drawbacks of systemic checkpoint inhibition and the potential for new intravesical and systemic therapies to improve outcomes. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.